MedPath

Surgical Site Infection Outcomes in Natural Orifice Intracorporeal Anastomosis and Extraction (NICE) Procedure - The NICE Trial

Conditions
Diverticulitis
Surgical Site Infection
Surgical Site Infections
Colorectal Surgery
Robotic Surgical Procedures
Clinical Trials
Diverticulitis, Colonic
Diverticulitis Colon
Diverticulitis; Perforation, Bowel
Registration Number
NCT06957236
Lead Sponsor
The Methodist Hospital Research Institute
Brief Summary

The goal of this observational study is to learn if a new surgical technique, called the NICE procedure, is as safe as standard methods for treating benign left-sided colon and rectal diseases in adults. The main question it aims to answer is:

Does the NICE procedure lead to similar or lower rates of surgical site infections (SSIs) within 30 days compared to traditional surgery?

Researchers will gather information from hospitals across the country to evaluate how well this procedure works when performed by experienced surgeons in everyday clinical settings.

Participants will:

Have surgery using the NICE procedure, which uses a robotic platform and removes the specimen through a natural opening (the rectum).

Be monitored for any infections or complications after surgery.

Complete surveys to track their recovery, bowel function, and quality of life for up to 6 months.

This study may help improve recovery, reduce pain, and lower infection risk in future colorectal surgeries.

Detailed Description

Background and Rationale The Natural Orifice Intracorporeal Anastomosis and Extraction (NICE) procedure represents an emerging innovation in minimally invasive colorectal surgery. It combines robotic intracorporeal anastomosis (ICA) with natural orifice specimen extraction (NOSE), typically transrectal, to avoid the need for an abdominal extraction incision. This approach may reduce surgical site trauma, postoperative pain, opioid use, and rates of incisional hernias.

Intracorporeal anastomosis has been widely studied in right-sided colectomies, with consistent evidence showing reduced surgical site infections (SSIs) and improved recovery. However, application to left-sided resections introduces unique challenges. The bacterial density in the left colon and rectum, combined with transrectal manipulation, may increase the risk of deep or organ-space SSIs. While early single-center experiences suggest the NICE procedure may be safe and effective, multicenter validation in a broader clinical setting is needed.

Study Objectives The primary objective of this study is to determine the 30-day incidence of surgical site infections (superficial, deep, and organ-space) in patients undergoing robotic left-sided colorectal resections using the NICE procedure. Secondary objectives include assessment of intraoperative technical performance, perioperative complications, postoperative recovery, and longer-term functional and quality of life outcomes.

Study Design This is a prospective, multicenter, observational cohort study enrolling patients undergoing elective robotic-assisted left colectomy or rectosigmoid resection for benign colorectal disease. All procedures will use the standardized NICE technique. Participating surgeons must have performed at least 20 prior NICE procedures. The study will run over a 24-month accrual period, with each patient followed for at least 6 months postoperatively.

Study Procedures Surgical intervention involves robotic left-sided resection with intracorporeal anastomosis and transrectal specimen extraction. All sites will follow a standardized Enhanced Recovery After Surgery (ERAS) protocol tailored to robotic colorectal surgery. Operative videos will be collected for quality control, ensuring adherence to the defined NICE procedural steps.

Postoperative follow-up includes in-person or remote assessments at 30 days, 3 months, and 12 months. Functional outcomes will be measured using validated questionnaires: Wexner score for fecal incontinence, LARS score for bowel dysfunction, and PROMS-10 for health-related quality of life.

Data Collection and Oversight Clinical data will be collected prospectively using REDCap, a secure, HIPAA-compliant electronic data capture system. All patient data will be pseudonymized. A centralized coordinating center will oversee data integrity, standardization, and site compliance. Surgical cases will be video recorded to ensure procedural fidelity.

Each site must consecutively enroll eligible patients and maintain compliance with protocol-defined ERAS standards. Surgeons will be credentialed based on review of unedited operative videos prior to participation.

Outcomes The primary outcome is the 30-day SSI rate, including superficial, deep, and organ-space infections. Secondary outcomes include intraoperative variables (e.g., operative time, blood loss, conversion rate), postoperative recovery (opioid use, length of stay, complications, readmissions, reinterventions), and long-term outcomes such as hernia formation and bowel function.

Patient-reported outcome measures will be collected preoperatively and at designated follow-up intervals. These include the Wexner score, LARS score, and PROMS-10, allowing for longitudinal evaluation of continence, function, and quality of life.

Sample Size and Statistical Considerations The study is powered to detect non-inferiority in SSI rates compared to conventional techniques. Assuming a historical SSI rate of 5% and a non-inferiority margin of 5%, a sample size of at least 224 patients provides 80% power with a 5% alpha. To accommodate multivariate modeling and variability across sites, the planned enrollment target is 300-400 patients.

Data will be analyzed using multilevel logistic regression to account for center and surgeon-level effects. Sensitivity analyses will be conducted to test robustness of findings. Descriptive and inferential analyses will be used to evaluate changes in quality of life and functional outcomes over time.

Significance This trial aims to provide high-quality evidence on the safety and performance of the NICE procedure for left-sided colorectal surgery. If non-inferiority is demonstrated, the findings may support broader adoption of this technique, with implications for faster recovery, reduced SSI risk, and improved patient experience. By incorporating video-based quality control and standardized ERAS pathways, the study ensures procedural consistency and real-world applicability of results.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
30-Day Surgical Site Infection (SSI) Rate Following the NICE Procedure30 days post-surgery

Measures the proportion of patients who develop surgical site infections (SSIs) categorized as superficial, deep, or organ-space within 30 days following robotic left-sided colectomy or rectosigmoid resection using the NICE procedure. Infections are classified per CDC definitions and assessed through clinical evaluation, medical records, and follow-up.

Secondary Outcome Measures
NameTimeMethod
Overall Postoperative Complication Rate30 days post-surgery

Proportion of patients who experience one or more postoperative complications, including minor and major events, within 30 days of surgery.

Reoperation or Re-intervention Rate30 days post-surgery

Proportion of patients who require unplanned surgical reoperation or interventional procedures (e.g., drainage) within 30 days post-surgery.

Readmission Rate Within 30 Days30 days post-surgery

Percentage of patients who are readmitted to any hospital for any cause within 30 days following the index surgery.

Postoperative Mortality Rate30 days post-surgery

Percentage of patients who die from any cause within 30 days following the surgical procedure.

Use of Transrectal Wound ProtectorDuring surgery

Documents whether a wound protector was used during transrectal specimen extraction as part of the NICE procedure.

Type of Intracorporeal Anastomosis Staple LineDuring surgery

Classifies the anastomosis as either crossing or non-crossing staple line configuration.

Change in Wexner Score for Fecal IncontinenceBaseline, 3 months, 12 months

Evaluates changes in the Wexner score from baseline at 3 and 12 months to assess the severity and frequency of fecal incontinence following the NICE procedure. The Wexner score assesses the ability to control gas, liquid, and solid stool, the need for protective garments, and the impact on lifestyle.

Scale Range: 0 (no incontinence) to 20 (complete incontinence); Higher scores indicate worse fecal incontinence.

Functional Outcomes: LARS ScoreBaseline, 3 months, 12 months

The Low Anterior Resection Syndrome (LARS) score assesses bowel dysfunction including incontinence, frequency, and urgency following low anterior resection. Evaluates changes over time.

Scale Range: 0 to 42; Scores 0-20 indicate no LARS, 21-29 minor LARS, and 30-42 major LARS. Higher scores indicate worse bowel dysfunction.

Health-Related Quality of Life: PROMS-10 ScoreBaseline, 3 months, 12 months

PROMS-10 captures patient-reported physical, emotional, and social well-being using a 10-item questionnaire. Monitors change in health-related quality of life over time.

Scale Range: 0 to 40; Higher scores indicate better quality of life.

Oversewing of AnastomosisDuring surgery

Indicates whether the anastomosis was reinforced with oversewing after stapling.

Performance of Mesenteric ShavingDuring surgery

Captures whether mesenteric shaving was performed on the specimen during the NICE procedure.

Length of Hospital Stay30 days post-surgery

Measures the number of days from the date of surgery to the date of discharge, assessing early recovery and discharge readiness.

Total Operative TimeDuring surgery

Measures the total duration of the NICE procedure from skin incision to closure, reported in minutes.

Success Rate of Intracorporeal AnastomosisDuring surgery

Captures whether the intracorporeal anastomosis (ICA) was successfully completed as intended using the robotic platform.

Success Rate of Transrectal Specimen ExtractionDuring surgery

Measures whether the surgical specimen was successfully extracted through the rectum without conversion to transabdominal extraction.

Incidence of Intraoperative ComplicationsDuring surgery

Reports the occurrence of intraoperative complications such as rectal tear, sphincter injury, or conversion to open surgery.

Total Opioid Use Within 30 Days Post-Surgery30 days post-surgery

Measures the cumulative opioid consumption during the first 30 days following surgery, expressed in morphine milligram equivalents (MME).

Long-Term Outcomes: Hernia, Bowel Dysfunction, Fecal IncontinenceUp to 6 months post-surgery

Monitors incidence of incisional hernia, long-term bowel dysfunction, and persistent fecal incontinence following the NICE procedure.

Stool Contamination Grade During NICE ProcedureDuring surgery

Assesses the degree of fecal contamination encountered intraoperatively using a standardized grading scale.

Scale Components and Interpretation:

Degree of Contamination (Severity of contamination encountered):

* 1 = Mild (Minimal stool, easily managed with minimal delay)

* 2 = Moderate (Requires additional cleaning, minor to moderate delays)

* 3 = Severe (Substantial contamination, extensive cleaning and procedural delay required) Higher scores indicate worse contamination.

Quality of Contamination (Consistency of stool):

* Liquid = Easily aspirated

* Semi-formed = Partially cleared with aspiration

* Solid = Requires transrectal/manual clearing

Degree of Evacuation (Effectiveness of stool clearance):

* Complete = All visible stool removed

* Semi-complete = Minimal residual stool

* Incomplete = Moderate residual stool

Estimated Intraoperative Blood LossDuring surgery

Records the estimated blood loss in milliliters during the NICE procedure as documented by the surgical team.

Trial Locations

Locations (1)

Houston Methodist Hospital

🇺🇸

Houston, Texas, United States

Houston Methodist Hospital
🇺🇸Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath